Alessia Spagnuolo
Avellino, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential?
Journal: Expert opinion on investigational drugs
Published: March 09, 2026
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer.
Journal: Expert opinion on pharmacotherapy
Published: February 12, 2025
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.
Journal: Translational lung cancer research
Published: November 29, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
Journal: BMC cancer
Published: February 20, 2021
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
Journal: Translational lung cancer research
Published: February 04, 2020
Combining immunotherapies to treat non-small cell lung cancer.
Journal: Expert review of respiratory medicine
Published: May 23, 2019
"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?
Journal: Journal of thoracic disease
Published: January 12, 2019
Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
Journal: Expert opinion on emerging drugs
Published: September 26, 2018
Lung cancer, elderly and immune checkpoint inhibitors.
Journal: Journal of thoracic disease
Published: June 29, 2018
Cancer drug related cardiotoxicity during breast cancer treatment.
Journal: Expert opinion on drug safety
Published: April 28, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026